The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; ...
Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
Nanomerics Ltd. announced the successful completion of its OC134 Phase I trial - the SUNLIGHT trial. With the clinical phase competed the trial for OC134 and the MET platform has met its primary ...